Locally Advanced Pancreatic Cancer Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the locally advanced pancreatic cancer market?
In recent times, there has been a swift expansion in the market size for locally advanced pancreatic cancer. Predictions indicate that it may expand from $0.95 billion in 2024 to $1.05 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.9%. This notable development during the historic period can be linked to factors such as heightened awareness about pancreatic cancer, advancements in chemotherapy protocols, increased use of targeted therapies, a surge in the occurrence of pancreatic cancer, the establishment of combined treatment plans, and improvements in supportive care choices.
What will be the locally advanced pancreatic cancer market size in the future?
Projected expansion in the locally advanced pancreatic cancer market, which is anticipated to reach $1.57 billion by 2029, evidences a robust compound annual growth rate (CAGR) of approximately 10.5%. Factors attributing to this significant growth over the predicted period include greater understanding and knowledge of pancreatic cancer, bettered chemotherapy schedules, expanding use of targeted therapies, an escalation in pancreatic cancer cases, advancement of combined treatment protocols, and improved alternatives for supportive care. Foreseen trends for this period encompass progress in immunotherapy, expansion of targeted therapies, advanced precision radiation methods, improved diagnostic imaging procedures, increased utilization of minimally invasive surgical techniques, the incorporation of artificial intelligence into treatment design, as well as advancements in combined therapy protocols.
Get your locally advanced pancreatic cancer market report here!
What main drivers are fueling expansion in the locally advanced pancreatic cancer market?
The growth of locally advanced pancreatic cancer markets is expected to be fueled by the surge in tobacco usage. Tobacco, a plant whose leaves are utilized in substances like cigarettes and cigars, contains nicotine which is highly addictive and associated with serious health complications including cancer and cardiovascular diseases. Factors like easy availability, affordability, promotion of tobacco, societal sanction in some regions, and anxiety-induced smoking are escalating its consumption. A significant correlation exists between tobacco usage and the increased risk of locally advanced pancreatic cancer, leading to the high incidence of pancreatic tumors. As reported by the Global Action to End Smoking, a U.S. nonprofit entity committed to research to cease the smoking epidemic, in 2022, approximately 62.9 million adults in the U.S. used tobacco, placing it globally fourth and first in the Americas. Additionally, approximately 11.5% of U.S. adults (28.3 million) consumed cigarettes, with higher proportions in males (13.1%) compared to females (10.1%). Thus, the locally advanced pancreatic cancer market is experiencing growth due to the rise in tobacco usage.
What key areas define the segmentation of the global locally advanced pancreatic cancer market?
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
Who are the dominant players expanding their reach in the locally advanced pancreatic cancer market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co
What are the key trends shaping the future of the locally advanced pancreatic cancer market?
Key players within the locally advanced pancreatic cancer market are concentrating their efforts on the creation of innovative products such as orphan drugs. These are aimed at improving treatment possibilities, enhancing patients’ outcomes, and addressing the unmet healthcare needs resulting from this aggressive disease. Orphan drugs, commonly used to treat rare diseases that affect a small population, are encouraged by regulatory authorities via perks such as tax reductions and exclusive market rights. Actuate Therapeutics Inc., an American biopharmaceutical firm, revealed in January 2025 that its new GSK-3ß inhibitor, Elraglusib, had been granted Orphan Drug Designation by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of pancreatic ductal adenocarcinoma (PDAC) (a potential type of locally advanced pancreatic cancer). The acknowledgment of Elraglusib underlines its potential to address a significant need in the treatment of this serious cancer type, particularly in light of encouraging Phase 2 trial outcomes demonstrating noteworthy clinical progress and anti-tumor responses in patients with metastatic PDAC.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214
Which regions are emerging as leaders in the locally advanced pancreatic cancer market?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Prenatal DNA Sequencing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/prenatal-dna-sequencing-global-market-report
Viral Vectors & Plasmid DNA Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Breast Cancer Drugs Global Market Report 2025
https://thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
